Company Overview: KERX

Upcoming Projects (KERX)

Don’t see a project related to the company you care about? Create your own!

Executed Projects (KERX)

Don’t see a project related to the company you care about? Create your own!

Expired Projects (KERX)

Exploring Keryx’s Auryxia in treating CKD anemia after Nov 6th PDUFA
Ticker: KERX
Execute By: Dec 06, 2017

Upcoming & Overdue Catalysts (KERX)

Don’t see a catalyst related to the company you care about? Create your own!

Occurred Catalysts (KERX)

Keryx Bio (KERX) Reported Data on Auryxia in patients with advanced kidney disease at the 55th annual ERA/EDTA congress in Copenhagen
Ticker: KERX
Occurred on: May 25, 2018
Ardelyx, Inc. Expected to Release Data in First Half of 2017 from Onset-of-Action Study Evaluating the Effect of RDX7675 on the Rate of Blood Potassium Lowering, Along with Safety and Efficacy, in Patients with Hyperkalemia - Discontinued
Tickers: ARDX, KERX
Occurred on: Nov 21, 2017
Keryx Biopharmaceuticals' (KERX) Auryxia in treating Iron deficiency anemia in non-dialysis dependent CKD patients PDUFA date expected November 6, 2017.
Ticker: KERX
Occurred on: Nov 07, 2017
Ardelyx, Inc. to Submit Detailed Results from Its First Phase 3 Trial Of Tenapanor for Hyperphosphatemia in End-Stage Renal Disease (ESRD) at The American Society Of Nephrology Kidney Week
Tickers: ARDX, KERX
Occurred on: Oct 11, 2017
Ardelyx'S Plans to Initiate The Second Phase 3 Study of Tenapanor for The Treatment Of Hyperphosphatemia in ESRD Patients on Dialysis in Mid-2017
Tickers: ARDX, KERX
Occurred on: Feb 15, 2017
Keryx (KERX) Plans to Submit FDA Application in Q3 to Expand Indication for Auryxia to Include the Treatment of Iron Deficiency Anemia in Adults With Stage 3-5 Non-Dialysis-Dependent Chronic Kidney Disease
Ticker: KERX
Occurred on: Jan 12, 2017
Ardelyx, Inc. Announces the Initiation of a Three Part Phase 3 Clinical Trial Evaluating RDX7675 In Patients with Hyperkalemia
Tickers: ARDX, KERX
Occurred on: Jan 03, 2017
Keryx (KERX) Plans to Present Detailed Phase 3 Data at Fourth Quarter Medical Conference on Auryxia in Treatment of Iron Deficiency Anemia in Adults With Non-Dialysis Dependent Chronic Kidney Disease
Ticker: KERX
Occurred on: Nov 17, 2016
Keryx Biopharmaceuticals announced an interruption in the supply of Auryxia (ferric citrate) tablets due to a production-related issue converting active pharmaceutical ingredient (API) to finished
Ticker: KERX
Occurred on: Aug 01, 2016
Phase 3 data of Auryxia for Iron deficiency anemia in non-dialysis dependent CKD patients due early 2Q 2016. April 30 is a BPC estimate based on early 2Q guidance
Ticker: KERX
Occurred on: Mar 29, 2016
Keryx (KERX) Announces Phase III Results Evaluating Auryxia for the Treatment of Iron Deficiency Anemia in Patients With Stage 3-5 Non-Dialysis-Dependent Chronic Kidney Disease
Ticker: KERX
Occurred on: Mar 29, 2016

Strategic Initiatives (KERX)

Don’t see a strategic initiative related to the company you care about? Create your own!

KERX Overview